STAT+: Genetics may shape GLP-1 outcomes, slightly

What’s Happening

Real talk: The traditional biotech venture model under pressure, PhRMA chief Ubl to exit, and other biotech news from The Readout Biotech Biotech STAT Plus: Biotech VCs, used to a winning formula in drug development, face disruption By Allison DeAngelis The Readout The Readout STAT Plus: Terns drug may not be as competitive as many initially thought By Elaine Chen Special Report Special Report STAT Plus: A decade ago, these drugs tore apart the FDA.

Today, they might be some patients best hope By Jason Mast The Readout The Readout STAT Plus: Novo Nordisk launches high-dose Wegovy By Elaine Chen Health Health STAT Plus: Many cancer patients don’t get genomic tests to guide treatment, study finds By Angus Chen STAT Plus: A decade ago, these drugs tore apart the FDA. What does it mean for patients? (yes, really)

By Casey Ross STAT Plus: Medicare Advantage plans win extra $18.

Why This Matters

6 billion as feds cut star ratings measures By Bob Herman STAT Plus: Everyone agrees AI scribes are increasing health care costs.

Medical professionals are taking note of this development.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

How do you feel about this development?